Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

What Was Tested

The paper reports a study of Angiotensin II Type 1 Receptor Blockers, published as a randomized controlled trial.

Here, the researchers report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Angiotensin II Type 1 Receptor Blockers study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II Type 1 Receptor Blockers study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Angiotensin II Type 1 Receptor Blockers could be set against what happens without it.

What Was Measured

Here, the researchers report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease.

Topics PubMed links to this paper include Angiotensin II Type 1 Receptor Blockers, Atrial Fibrillation, Electrocardiography, Germany, Imidazoles, Incidence and Tachycardia, Paroxysmal.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II Type 1 Receptor Blockers.

The abstract goes on to report its results in about 13 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Circulation. Arrhythmia and electrophysiology), a journal based in United States.

More context: all human trials.